Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 10/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.41 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1894319 | 0.88 | NAMPT (0.44) | MAPKAPK2NAMPTCYP17A1PSMB8RORC | |
| SCHEMBL26640219 | 0.83 | NAMPT (0.45) | MAPKAPK2NAMPTCYP17A1PSMB8RORC | |
| SCHEMBL16245958 | 0.82 | NAMPT (0.47) | MAPKAPK2NAMPTCYP17A1SREBF2PSMB8 | |
| SCHEMBL16246318 | 0.82 | MAPKAPK2 (0.40) | MAPKAPK2NAMPT | |
| SCHEMBL27167710 | 0.81 | CYP17A1 (0.51) | NAMPTCYP17A1PSMB8 | |
| SCHEMBL16246250 | 0.81 | NAMPT (0.46) | MAPKAPK2NAMPTCYP17A1SREBF2PSMB8 | |
| SCHEMBL29850092 | 0.79 | NAMPT (0.49) | MAPKAPK2NAMPTCYP17A1SREBF2PSMB8 | |
| SCHEMBL853159 | 0.79 | NAMPT (0.49) | MAPKAPK2NAMPTCYP17A1SREBF2PSMB8 | |
| SCHEMBL17247383 | 0.79 | MAPKAPK2 (0.53) | MAPKAPK2NAMPTCYP17A1SREBF2PSMB8 | |
| SCHEMBL14260617 | 0.78 | NAMPT (0.48) | MAPKAPK2NAMPTCYP17A1PSMB8MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2994470-B1 | PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9630963-B2 | Quinolone derivatives as fibroblast growth factor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-20160130268-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2016-05-12 | — | — | US | disclosed |
| EP-2994470-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS | Principia Biopharma Inc. (US) | 2016-03-16 | — | — | EP | disclosed |
| WO-2014182829-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130268-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS | FGFR1, FGFR3, FGFR2 | MAPKAPK2 1497/4885NAMPT 833/4885CYP17A1 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.